There is more competition in play for Emgality from Lundbeck’s new intravenous CGRP drug Vyepti (eptinezumab), which requires less frequent dosing of Emgality as well as Aimovig and Ajovy ...
Eli Lilly’s third-to-market migraine prevention drug Emgality has a lot of ground to make up on its rivals, but a new study in people who have failed earlier migraine therapies could help.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback